Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KMEDIUM RiskNeutral

Abbott Laboratories

abbott.com
Filed: Mar 9, 2026Campbell, DelawareCIK: 0000001800Manufacturing
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Abbott Laboratories issued $20 billion in senior notes across multiple tranches on March 9, 2026, to strengthen its financial position and provide liquidity for operations and growth initiatives.

Key Takeaways

Abbott raised $20 billion through a public offering of senior notes with maturities ranging from 2029 to 2033

The offering included four tranches: $1B floating rate notes due 2029, $2.25B at 3.700% due 2029, $2.5B at 4.000% due 2031, and $2.75B at 4.300% due 2033

2 more takeaways

Related Filings (2)

2 more filings from Abbott Laboratories in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 9, 2026
Item1.01
CategoryMaterial Agreement
CIK0000001800
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
debt financingmaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings